Treatments for Advanced Non-Small-Cell Lung Cancer
Author Information
Author(s): Nicholas Thatcher, Aldo Castagnari
Primary Institution: University of Manchester, Christie Hospital NHS Trust
Conclusion
Erlotinib is an effective treatment option for patients with advanced non-small-cell lung cancer, showing similar efficacy to chemotherapy with better tolerability and improved quality of life.
Supporting Evidence
- Erlotinib showed a median survival of 6.7 months compared to 4.7 months with placebo.
- The one-year survival rate was 31% with erlotinib versus 21% with placebo.
- Erlotinib was associated with significant improvements in quality of life compared to placebo.
Takeaway
This study looks at how to treat lung cancer that has spread. It finds that a medicine called erlotinib can help people live longer and feel better compared to other treatments.
Methodology
The study reviews various therapeutic options and analyzes data from multiple trials, including the BR.21 trial, which assessed erlotinib's efficacy.
Potential Biases
Potential bias may arise from the selection of studies included in the review and the focus on specific treatment regimens.
Limitations
The study primarily focuses on erlotinib and may not encompass all treatment options available for advanced non-small-cell lung cancer.
Participant Demographics
The study includes patients with advanced non-small-cell lung cancer, with a focus on elderly patients and those with varying performance statuses.
Statistical Information
P-Value
p < 0.001
Confidence Interval
0.68–0.99
Statistical Significance
p < 0.001
Want to read the original?
Access the complete publication on the publisher's website